Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee

Autoimmune diseases (ADs) are characterized by loss of immune tolerance, high chronicity, with substantial morbidity and mortality, despite conventional immunosuppression (IS) or targeted disease modifying therapies (DMTs), which usually require repeated administration. Recently, novel cellular ther...

Full description

Saved in:
Bibliographic Details
Published in:EClinicalMedicine 2024-03, Vol.69, p.102476-102476, Article 102476
Main Authors: Greco, Raffaella, Alexander, Tobias, Del Papa, Nicoletta, Müller, Fabian, Saccardi, Riccardo, Sanchez-Guijo, Fermin, Schett, Georg, Sharrack, Basil, Snowden, John A., Tarte, Karin, Onida, Francesco, Sánchez-Ortega, Isabel, Burman, Joachim, Castilla Llorente, Cristina, Cervera, Ricard, Ciceri, Fabio, Doria, Andrea, Henes, Jörg, Lindsay, James, Mackensen, Andreas, Muraro, Paolo A., Ricart, Elena, Rovira, Montserrat, Zuckerman, Tsila, Yakoub-Agha, Ibrahim, Farge, Dominique
Format: Article
Language:English
Subjects:
Autoimmune diseases
Chimeric antigen receptor (CAR) T cells
Chimeric antigen receptor (CAR) T cells
Life Sciences
Mesenchymal stem cells
Regulatory T cells
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Autoimmune diseases (ADs) are characterized by loss of immune tolerance, high chronicity, with substantial morbidity and mortality, despite conventional immunosuppression (IS) or targeted disease modifying therapies (DMTs), which usually require repeated administration. Recently, novel cellular therapies (CT), including mesenchymal stromal cells (MSC), Chimeric Antigen Receptors T cells (CART) and regulatory T cells (Tregs), have been successfully adopted in ADs. An international expert panel of the European Society for Blood and Marrow Transplantation and the International Society for the Cell and Gene Therapy, reviewed all available evidence, based on the current literature and expert practices, on use of MSC, CART and Tregs, in AD patients with rheumatological, neurological, and gastroenterological indications. Expert-based consensus and recommendations for best practice and quality of patient care were developed to support clinicians, scientists, and their multidisciplinary teams, as well as patients and care providers and will be regularly updated.
ISSN:2589-5370
2589-5370
DOI:10.1016/j.eclinm.2024.102476